Evidence map›Paper›PMID 29672628›Full record

ArticlePloS one2018

Derivation and internal validation of a mortality risk index for aged people living with HIV: The Dat'AIDS score.

Maxime Hentzien, Cyrille Delpierre, Pascal Pugliese, Clotilde Allavena, Christine Jacomet, Marc-Antoine Valantin, André Cabié, Lise Cuzin, David Rey, Firouzé Bani-Sadr and 2 more

Abstract readMulticenter StudyValidation Study
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maxime HentzienDepartment of Internal Medicine, Infectious Diseases, and Clinical Immunology, Robert Debré Hospital, Reims Teaching Hospitals, Reims, France.ORCID 0000-0003-2729-9420
Cyrille DelpierreUMR1027, INSERM, Université Toulouse III Paul-Sabatier, Toulouse, France.
Pascal PuglieseInfectious Diseases Department, CHU L'Archet, University of Nice, Nice, France.
Clotilde AllavenaInfectious Diseases Department, CHU Hôtel Dieu, University of Nantes, Nantes, France.
Christine JacometDepartment of Infectious and Tropical Diseases, Gabriel-Montpied Hospital, Clermont-Ferrand Teaching Hospitals, Clermont-Ferrand, France.
Marc-Antoine ValantinDepartment of Infectious and Tropical Diseases, La Pitié-Salpêtrière Hospital, Paris Teaching Hospitals, Paris, France.
André CabiéDepartment of Infectious and Tropical Diseases, Fort-De-France Hospital, Martinique Teaching Hospitals, Fort-De-France, Martinique, France.
Lise CuzinUMR1027, INSERM, Université Toulouse III Paul-Sabatier, Toulouse, France.
David ReyHIV Care Center, Nouvel Hôpital Civil, Hôpitaux universitaires de Strasbourg, Strasbourg, France.
Firouzé Bani-SadrDepartment of Internal Medicine, Infectious Diseases, and Clinical Immunology, Robert Debré Hospital, Reims Teaching Hospitals, Reims, France.
Moustapha DraméEA 3797, Faculty of Medicine, University of Reims Champagne-Ardenne, Reims, France.
Dat’Aids Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe objective was to develop a multivariable prognostic index for overall mortality over a five-year span integrating classical HIV biomarkers and comorbidities in people living with HIV (PLHIV) aged 60 or older.

designProspective multicenter cohort study from the French Dat'AIDS cohort.

methodsAll HIV-1 infected patients aged 60 years or older on 1st January 2008 were included. Sociodemographic data, CD4 cell count, CD4 nadir, HIV viral load, history of comorbidities, hepatitis co-infections and laboratory parameters at baseline were considered as potential prognostic variables. Primary outcome was all-cause mortality.

resultsAmong 1415 patients included, we derived a score comprising the following predictors: Age (65-74: 1 point; ≥75: 8 points), CD4 cell count (200-349: 3 points; <200: 6 points), non-HIV related cancer (6 points), cardiovascular disease (8 points), estimated glomerular filtration rate (30-59 mL/min/1.73m2: 5 points; <30mL/min/1.73m2: 16 points), cirrhosis (13 points), low body mass index (<18.5 kg/m2, 10 points), anemia (6 points). Mean observed score was 7.0 ± 8.0 and ranged from 0 to 45. Score categories defined 4 risk groups for mortality: low, moderate, high and very high risk (5-year survival probability 0.95 (95%CI[0.93-0.97]), 0.90 (95%CI[0.87-0.92]), 0.77 (95%CI[0.68-0.84]) and 0.54 (95%CI[0.43-0.63]) respectively). The score showed good discrimination (C-statistic = 0.76) and calibration.

conclusionsWe propose a multivariable prognostic score for mortality among PLHIV aged 60 or over, who will become the predominant population in future years in western populations. It could be a useful tool for research, for developing preventive and treatment strategies according to risk group, and for risk assessment by clinicians.

Indexed as

AgedCD4 Lymphocyte CountCohort StudiesComorbidityFemaleFranceHIV-1HIV InfectionsHumansMaleMiddle AgedMultivariate AnalysisPrognosisProportional Hazards ModelsProspective StudiesRisk Factors

Identifiers

PMID29672628
PMCPMC5908189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.